These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12980987)

  • 1. DOPA decarboxylase inhibition through the interaction of coenzyme and substrate.
    SCHOTT HF; CLARK WG
    J Biol Chem; 1952 May; 196(1):449-62. PubMed ID: 12980987
    [No Abstract]   [Full Text] [Related]  

  • 2. Studies on dopa decarboxylase inhibitors in vivo by use of C14-carboxyl-labeled dopa.
    HANSSON E; CLARK WG
    Proc Soc Exp Biol Med; 1962 Dec; 111():793-8. PubMed ID: 13952652
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of aromatic L-amino acid decarboxylase by coenzyme-amino acid adducts.
    Rudd EA; Thanassi JW
    Biochemistry; 1981 Dec; 20(26):7469-75. PubMed ID: 7326239
    [No Abstract]   [Full Text] [Related]  

  • 4. New pathway for metabolism of dopa.
    O'Leary MH; Baughn RL
    Nature; 1975 Jan; 253(5486):52-3. PubMed ID: 1167399
    [No Abstract]   [Full Text] [Related]  

  • 5. [Action of some DOPA decarboxylase inhibitors with reference to different types of convulsions].
    HEROLD M; CAHN J; HELBECQUE C; KABACOFF O
    C R Seances Soc Biol Fil; 1962; 156():1273-6. PubMed ID: 13954030
    [No Abstract]   [Full Text] [Related]  

  • 6. Decarboxylation of 3,4-dihydroxyphenylalanine by oxyhemoglobin.
    Yamabe H; Lovenberg W
    Biochem Biophys Res Commun; 1972 May; 47(4):733-9. PubMed ID: 5063594
    [No Abstract]   [Full Text] [Related]  

  • 7. Failure of vitamin B6 to reverse the L-dopa effect in patients on a dopa decarboxylase inhibitor.
    Klawans HL; Ringel SP; Shenker DM
    J Neurol Neurosurg Psychiatry; 1971 Dec; 34(6):682-6. PubMed ID: 5158783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coenzyme--substrate adducts as inhibitors of mouse liver 3,4-dihydroxyphenylalanine decarboxylase.
    Rudd EA; Cunningham WC; Thanassi JW
    J Med Chem; 1979 Mar; 22(3):233-7. PubMed ID: 423204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The enzymatic decarboxylation of DOPA in human liver homogenates.
    Vogel WH; Snyder R; Hare TA
    Proc Soc Exp Biol Med; 1970 Jun; 134(2):477-81. PubMed ID: 5310151
    [No Abstract]   [Full Text] [Related]  

  • 10. How does L-dopa work in parkinsonism?
    Sandler M
    Lancet; 1971 Apr; 1(7703):784. PubMed ID: 4101278
    [No Abstract]   [Full Text] [Related]  

  • 11. Activation of DOPA decarboxylase by pyridoxal phosphate.
    AWAPARA J; SANDMAN RP; HANLY C
    Arch Biochem Biophys; 1962 Sep; 98():520-5. PubMed ID: 13863437
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacological antagonism between pyridoxal 5-phosphate (activator of DOPA decarboxylase) and certain hydrazines (inhibitors of monoamine oxidase)].
    LEVY J; MICHEL-BER E
    C R Hebd Seances Acad Sci; 1960 Jun; 250():4061-3. PubMed ID: 14416402
    [No Abstract]   [Full Text] [Related]  

  • 13. L-3,4-dihydroxyphenylalanine metabolism by the gut in vitro.
    Rivera-Calimlim L; Morgan JP; Dujovne CA; Bianchine JR; Lasagna L
    Biochem Pharmacol; 1971 Nov; 20(11):3051-7. PubMed ID: 5132112
    [No Abstract]   [Full Text] [Related]  

  • 14. [On the purification and specificity of DOPA-decarboxylase].
    WERLE E; AURES D
    Hoppe Seylers Z Physiol Chem; 1959 Sep; 316():45-60. PubMed ID: 13844020
    [No Abstract]   [Full Text] [Related]  

  • 15. Transamination is a major pathway of L-dopa metabolism following peripheral decarboxylase inhibition.
    Sandler M; Johnson RD; Ruthven CR; Reid JL; Calne DB
    Nature; 1974 Feb; 247(5440):364-6. PubMed ID: 4817854
    [No Abstract]   [Full Text] [Related]  

  • 16. Are dihydroxphenylalanine decarboxylase and 5-hydroxytrptophan decarboxylase individual enzymes?
    ROSENGREN E
    Acta Physiol Scand; 1960 Aug; 49():364-9. PubMed ID: 13743456
    [No Abstract]   [Full Text] [Related]  

  • 17. Microdialysis monitoring of 3,4-dihydroxyphenylalanine accumulation after decarboxylase inhibition: a means to estimate in vivo changes in tyrosine hydroxylase activity of the rat locus ceruleus.
    Robert F; Lambás-Señas L; Ortemann C; Pujol JF; Renaud B
    J Neurochem; 1993 Feb; 60(2):721-9. PubMed ID: 8093483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observations on the substrate specificity of DOPA decarboxylase from ox adrenal medulla, human phaeochromocytoma and human argentaffinoma.
    HAGEN P
    Br J Pharmacol Chemother; 1962 Feb; 18(1):175-82. PubMed ID: 13903593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The effect of thyroxin and starvation on the activity of amine oxidase and DOPA-decarboxylase in liver].
    HOLTZ P; STOCK K; WESTERMANN E
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1956; 228(3):322-30. PubMed ID: 13334654
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of LSD and 2-bromo LSD on the DOPA accumulation after central and peripheral decarboxylase inhibition.
    Hollunger G; Persson SA
    Eur J Pharmacol; 1975 Mar; 31(1):156-8. PubMed ID: 1126375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.